Clot removal device tested for sudden blood clots in the lungs
Tests the AlphaVac suction device in adults with acute pulmonary embolism.
Key facts
- Who runs it
- Angiodynamics, Inc.
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
- Status
- Recruiting
- People taking part
- 256 people, planned
- Started
- 15 Jun 2025
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
- Record updated
- 26 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden blood clot in the lungs (acute pulmonary embolism) that strains the right side of the heart. Everyone gets clot removal with the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Acute pulmonary embolism with symptoms for at most 14 days. A CT scan of the lung arteries (CTPA) must show a clot in at least one main or proximal lobar pulmonary artery. RV/LV diameter ratio ≥ 1.0 on CTPA. Also at least one of: heart rate ≥ 100 BPM on ECG (not due to low blood volume, irregular heartbeat or sepsis); systolic blood pressure ≤ 110mmHg for at least 15 minutes; breathing rate > 20 breaths per minute; oxygen saturation (SpO2) < 90% (or arterial oxygen pressure < 60 mmHg) at rest on room air; known history of heart failure.
- Earlier treatment
- No advanced clot-clearing treatment for pulmonary embolism (such as clot-dissolving drugs, surgery or catheter treatment) within 30 days before the procedure.
- Biomarker or test result
- Blood troponin level above the upper limit of normal.
Main reasons for not taking part
- Cannot take blood-thinning treatment
- Other illness with life expectancy under 1 year, or a do-not-resuscitate order
- Pregnant or breastfeeding
- Bleeding disorder or platelet count < 100,000/μL
- Clot in transit, IVC filter, need for ECMO, or recent cardiac arrest without recovery of consciousness
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Symptomatic, CTPA-proven acute PE with a maximum duration of symptoms of 14 days, showing a filling defect in at least one main or proximal lobar pulmonary artery
- RV/LV diameter ratio ≥ 1.0 assessed by CTPA
- Serum troponin levels above upper limit of normal as per hospital policy
- ≥ 18 years of age
- At least one of the following:; Electrocardiogram (ECG)-documented tachycardia with heart rate ≥ 100 BPM, not due to hypovolemia, arrhythmia or sepsis; Systolic blood pressure ≤ 110mmHg for at least 15 minutes; Respiratory rate > 20 breaths per minuted. Oxygen saturation on pulse oximetry (SpO2) < 90% (or partial arterial oxygen pressure < 60 mmHg) at rest while breathing room air; Known history of heart failure
- Willing and able to provide written informed consent prior to receiving study specific procedures
Who cannot take part
- Participation in another investigational drug or device study that study may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
- Any advanced reperfusion therapy for pulmonary embolism within 30 days of the index procedure (e.g lysis, surgery, catheter intervention)
- Any comorbid diagnosis consistent with a life expectancy of less than 1 year (e.g., stage 4 cancer)
- Cardiac arrest within last 14 days without documented evidence of recovery of conscious level to Glasgow Coma Scale >12
- Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow- up requirements, or that could impact the scientific integrity of the study
- History of congenital or acquired bleeding disorder predisposing to hemorrhagic state
- Platelet count < 100,000/μL
- A contraindication to therapeutic anticoagulation
- Known serious, uncontrolled sensitivity to radiographic agents
- Indication for ECMO
- Pregnant or breastfeeding
- A known clot in transit
- IVC filter
- A do not resuscitate limitation at inclusion in the study
- Deprived of liberty or under court protection
This trial is currently available in Poland.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy, safety, and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for the treatment of acute pulmonary embolism.
The group in the trial
- Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PETreatment being tested
Prospective single-arm trial reporting the efficacy, safety, and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for the treatment of acute pulmonary embolism.
Treatment: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
- Plain-language title
- Clot removal device tested for sudden blood clots in the lungsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 26 September 2025